Pyxis Oncology files Form 3 beneficial ownership statement for GordonMD Global Investments LP

• Pyxis Oncology Form 3 disclosed GordonMD Global Investments as a 10% owner, reporting indirect ownership of 10,024,909 common shares.
• Filing also reported 4,900,039 common stock purchase warrants, expiring July 2, 2029, with an exercise price of $3.29.
• Warrants become exercisable on the earlier of the issuer’s first public MICVO Phase 1 monotherapy data disclosure or Oct. 1, 2026.
• Event date was June 30, 2026; the statement was signed July 10, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000919574-26-004386), on July 10, 2026, and is solely responsible for the information contained therein.